Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2015
Date:2/4/2016

MARLBOROUGH, Mass., Feb. 4, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant currency basis, excluding divested businesses) and 5 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.26 for the period, compared to $0.22 a year ago, and reported a GAAP loss of $(0.11) per share, compared to a GAAP loss of $(0.23) a year ago.

For the year ended December 31, 2015, the company achieved full year sales of $7.477 billion, representing 8 percent operational revenue growth and 1 percent revenue growth on a reported basis. The company delivered full year adjusted earnings per share of $0.93, compared to $0.84 in 2014 and reported a GAAP loss of $(0.18) per share, compared to a GAAP loss of $(0.09) in the prior year period.

"Our accomplishments in 2015 demonstrate our continued momentum and track record of consistent performance across our businesses and geographies," said Mike Mahoney, president and chief executive officer, Boston Scientific. "The products and programs we brought to market through organic development and acquisitions, complemented by our innovative pipeline and continued global expansion, will benefit even more patients in 2016 and beyond."

Fourth quarter financial results and recent developments:

  • Achieved fourth quarter sales of $1.978 billion, compared to the company's guidance range of $1.970 to $2.010 billion, representing 10 percent operational revenue growth and 5 percent revenue growth on a reported basis, all compared to the prior year period.
  • Grew organic revenue 5 percent in the fourth quarter over the prior year period. Organic revenue growth excludes the impact of sales from divested businesses, changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems (AMS) male urology portfolio.
  • Delivered fourth quarter adjusted earnings per share of $0.26, compared to the guidance range of $0.23 to $0.25 per share, and reported a GAAP loss of $(0.11) per share compared to the company's guidance range of $0.10 to $0.13 per share, primarily due to litigation-related charges.
  • Achieved fourth quarter operational revenue growth of 23 percent in MedSurg (7 percent organic), 7 percent operational and organic revenue growth in Cardiovascular, and flat sales on an operational and organic basis in Rhythm Management, all on a constant currency basis over the prior year period.
  • Delivered strong operational revenue growth across all three major regions. Achieved 12 percent growth in the U.S. (5 percent organic), 10 percent growth in Europe (5 percent organic) and 7 percent growth (6 percent organic) in AMEA (Asia, Middle East and Africa), all on a constant currency basis over the prior year period. Delivered 16 percent operational revenue growth (15 percent organic) in Emerging Markets.
  • Launched the SYNERGY™ Stent System in the United States and Japan and initiated the EVOLVE Short DAPT clinical trial to assess the duration of dual anti-platelet therapy (DAPT) in patients receiving a bioabsorbable polymer drug-eluting stent. Gained SYNERGY™ reimbursement in France, the largest drug-eluting stent market in Europe by revenue.
  • Completed enrollment in REPRISE-III, a randomized, controlled trial designed to support U.S. regulatory approval for the Lotus™ Valve System for Transcatheter Aortic Valve Replacement (TAVR).*
  • Acquired the interventional radiology portfolio of CeloNova Biosciences, including its portfolio of drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to malignant tumors and other spherical embolic products for uterine fibroids, among other conditions.**
  • Launched the AngioJet™ ZelanteDVT™ Thrombectomy Catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins, in the United States and Europe.
  • Launched the LithoVue™ Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder, in the U.S. and Europe.
  • Received CE mark for and began the European launch of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure Device, which is designed with a lower profile, a closed end and may be fully recaptured and repositioned.***
  • Unveiled data demonstrating a 70 percent greater reduction in back pain relief for patients using the Precision Spectra™ Spinal Cord Stimulator System compared to the previous generation Precision Plus™ system.
  • Announced a collaboration with Accenture Digital Health to offer hospitals ADVANTICS™ Care Pathway Transformation, a data-driven digital health solution to help improve outcomes and reduce costs to treat patients with chronic cardiovascular conditions.
  • * In the U.S., the Lotus Valve System is an investigational device and not available for sale. It is CE marked in the European Union.
    ** Drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors are currently not available for sale in the U.S.
    *** The WATCHMAN FLX Device is not available for sale in the U.S. It is CE marked in the European Union.

    Worldwide sales for the fourth quarter: Three Months EndedChangeDecember 31,As Reported BasisLess: Impact of
    Foreign CurrencyConstant Currency Basisin millions

    2015

    2014Interventional Cardiology

    $

    525$

    5230

    %$

    (33)(6)

    %6%Peripheral Interventions

    2312224

    %(13)(6)

    %10%Cardiovascular7567451

    %(46)(6)

    %7%Cardiac Rhythm Management

    440468(6)

    %(24)(5)

    %(1)%Electrophysiology

    61593

    %(3)(5)

    %8%Rhythm Management501527(5)

    %(27)(5)

    %0%Endoscopy

    3433401

    %(21)(6)

    %7%Urology and Pelvic Health

    23714069

    %(14)(8)

    %77%Neuromodulation

    1411345

    %(2)(2)

    %7%MedSurg72161418

    %(37)(5)

    %23%Subtotal Core Businesses1,9781,8865

    %(110)(5)

    %10%Divested Businesses

    1N/AN/AN/AWorldwide Net Sales$

    1,978$

    1,8875

    %$

    (110)(5)

    %10%Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.Sales growth rates that exclude the impact of sales from divested businesses and/or changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.


    On a consolidated GAAP basis, net loss for the fourth quarter of 2015 was $142 million, or $(0.11) per share. These results included acquisition- and divestiture-, litigation-, and restructuring and restructuring-related net charges, discrete tax items and amortization expense of $504 million (after-tax) or $0.37 per share. Adjusted net income for the fourth quarter of 2015, excluding these net charges, was $362 million, or $0.26 per share.

    On a consolidated GAAP basis, net loss for the fourth quarter of 2014 was $299 million, or $(0.23) per share. These results included intangible asset impairment charges, acquisition- and divestiture-, litigation-, and restructuring and restructuring-related net charges, discrete tax items and amortization expense, of $602 million (after-tax) or $0.45 per share. Adjusted net income for the fourth quarter of 2014, excluding these net charges, was $303 million, or $0.22 per share.

    Worldwide sales for the full year:Twelve Months EndedChangeDecember 31,As Reported BasisLess: Impact of
    Foreign CurrencyConstant Currency Basisin millions

    2015

    2014Interventional Cardiology

    $

    2,033$

    2,057(1)

    %$

    (174)(8)

    %7

    %Peripheral Interventions

    9048506

    %(60)(7)

    %13

    %Cardiovascular2,9372,9071

    %(234)(8)

    %9

    %Cardiac Rhythm Management

    1,8071,912(5)

    %(117)(6)

    %1

    %Electrophysiology

    2332272

    %(14)(7)

    %9

    %Rhythm Management2,0402,139(5)

    %(131)(6)

    %1

    %Endoscopy

    1,3061,323(1)

    %(96)(7)

    %6

    %Urology and Pelvic Health

    69353530

    %(35)(6)

    %36

    %Neuromodulation

    5014726

    %(9)(2)

    %8

    %MedSurg2,5002,3307

    %(140)(6)

    %13

    %Subtotal Core Businesses7,4777,3761

    %(505)(7)

    %8

    %Divested Businesses

    4N/AN/AN/AWorldwide Net Sales$

    7,477$

    7,3801

    %$

    (505)(7)

    %8

    %Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.Sales growth rates that exclude the impact of sales from divested businesses and/or changes in foreign currency exchange rates are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.


    On a consolidated GAAP basis, net loss for the full year 2015 was $239 million, or $(0.18) per share. These results included intangible asset impairment charges, acquisition- and divestiture-, litigation-, restructuring and restructuring-related charges, pension termination charges, debt extinguishment charges, discrete tax items and amortization expense, of $1.506 billion (after-tax) or $1.11 per share. Adjusted net income for the full year 2015, excluding these net charges, was $1.267 billion, or $0.93 per share.

    On a consolidated GAAP basis, net loss for the full year 2014 was $119 million, or $(0.09) per share. These results included intangible asset impairment charges, litigation-, restructuring and restructuring-related charges, acquisition- and divestiture-related net credits, discrete tax items and amortization expense, of $1.248 billion (after-tax) or $0.93 per share. Adjusted net income for the full year 2014, excluding these net charges, was $1.129 billion, or $0.84 per share.

    Guidance for Full Year and First Quarter 2016

    The company estimates revenue for the full year 2016 to be in a range of $7.900 to $8.100 billion, which versus the prior year period, represents a growth range of approximately 6 to 8 percent on a reported basis, a growth range of approximately 7 to 10 percent on an operational basis, and a growth range of approximately 4 to 7 percent on an organic basis. The company estimates income on a GAAP basis in a range of $0.62 to $0.67 per share, and adjusted earnings, excluding acquisition- and divestiture-, restructuring- and restructuring-related charges, and amortization expense, in a range of $1.03 to $1.07 per share.

    The company estimates sales for the first quarter of 2016 in a range of $1.890 to $1.940 billion. The company estimates earnings on a GAAP basis in a range of $0.11 to $0.13 per share. Adjusted earnings, excluding acquisition- and divestiture-, restructuring- and restructuring-related charges, and amortization expense, are estimated in a range of $0.23 to $0.25 per share.

    Conference Call Information

    Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET). The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

    About Boston Scientific

    Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, GAAP earnings and adjusted earnings for the first quarter and full year 2016; our financial performance; our business plans; and our positioning for revenue and earnings growth. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

    Use of Non-GAAP Financial Information

    0

    GOOD


    Related medicine technology :

    1. Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
    2. Boston Scientific Announces Collaboration with Pelvic Floor Disorders Network to Study Treatment Strategies for Uterine Prolapse
    3. Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology
    4. Approval Of Boston Scientifics Watchman Device Will Support Rapid Growth In The Global Heart Defect Closure Device Market
    5. FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St. Jude, ResMed, and GenMark
    6. Boston Biomedical announces the Grand Opening of its Cambridge Headquarters
    7. Abilities Expo--the Nations Leading Event for People with Disabilities--Makes Boston Debut September 20-22
    8. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
    9. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
    10. OrbusNeich, Boston Scientific Settle Patent Litigation
    11. Boston Scientific Opens Institute For Advancing Science, Innovation Center In Shanghai
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/2/2020)... Wis. (PRWEB) , ... April 02, 2020 , ... ... temporary hospitals, Kenall introduces the KRT Series, a portable, durable luminaire using Indigo-Clean ... killing harmful bacteria, bolstering existing cleaning and infection prevention protocols, and reducing harmful ...
    (Date:4/1/2020)... , ... April 01, 2020 , ... Care Station Medical ... Group has implemented a number of changes to better care for our community. As ... our office hours and crafted new ways to offer medical care to patients coping ...
    (Date:4/1/2020)... ... April 01, 2020 , ... ... sign up today, with the first live-streaming broadcast premiering on April 2. , ... a host interviewing a variety of animal keepers and veterinary hospital staff with ...
    Breaking Medicine Technology:
    (Date:4/9/2020)... (PRWEB) , ... April 09, 2020 , ... T1 ... to assist in providing support to shelter residents, and anyone who may be experiencing ... crisis hotline remains fully operational as many families and individuals struggle with increased financial, ...
    (Date:4/7/2020)... ... 07, 2020 , ... Black Jaguar-White Tiger Foundation, the global non-profit is launching ... Jaguar-White Tiger Hemp consists of a chewable tablet and tincture available in a morning ... has launched. , “It is my great Honor, to finally introduce to you, what ...
    (Date:4/5/2020)... ... April 04, 2020 , ... ... (Three Wire), is uniting with the Yellow Ribbon Fund (YRF) to offer mental ... the organization. By continuing an ongoing partnership to launch a new initiative throughout ...
    (Date:4/2/2020)... ... 02, 2020 , ... FDA CDS Software Regulation:, The Latest ... 1:30-3:00 p.m. EDT, https://www.fdanews.com/cdssoftwareregulation , *NEW: The webinar ... management of the Coronavirus.* , Is one’s software regulated as a medical device? ...
    (Date:4/2/2020)... ... 2020 , ... Representatives fighting for children born exposed ... and guardians, to file a proof of claim in order to qualify to ... available by Purdue as part of its bankruptcy settlement. , “The COVID-19 national ...
    Breaking Medicine News(10 mins):